Cargando…

PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms

Adaptive, seamless, multisponsor, multitherapy clinical trial designs executed as large scale platforms, could create superior evidence more efficiently than single‐sponsor, single‐drug trials. These trial PIPELINEs also could diminish barriers to trial participation, increase the representation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Trusheim, MR, Shrier, AA, Antonijevic, Z, Beckman, RA, Campbell, RK, Chen, C, Flaherty, KT, Loewy, J, Lacombe, D, Madhavan, S, Selker, HP, Esserman, LJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5142736/
https://www.ncbi.nlm.nih.gov/pubmed/27643536
http://dx.doi.org/10.1002/cpt.514
_version_ 1782472820870086656
author Trusheim, MR
Shrier, AA
Antonijevic, Z
Beckman, RA
Campbell, RK
Chen, C
Flaherty, KT
Loewy, J
Lacombe, D
Madhavan, S
Selker, HP
Esserman, LJ
author_facet Trusheim, MR
Shrier, AA
Antonijevic, Z
Beckman, RA
Campbell, RK
Chen, C
Flaherty, KT
Loewy, J
Lacombe, D
Madhavan, S
Selker, HP
Esserman, LJ
author_sort Trusheim, MR
collection PubMed
description Adaptive, seamless, multisponsor, multitherapy clinical trial designs executed as large scale platforms, could create superior evidence more efficiently than single‐sponsor, single‐drug trials. These trial PIPELINEs also could diminish barriers to trial participation, increase the representation of real‐world populations, and create systematic evidence development for learning throughout a therapeutic life cycle, to continually refine its use. Comparable evidence could arise from multiarm design, shared comparator arms, and standardized endpoints—aiding sponsors in demonstrating the distinct value of their innovative medicines; facilitating providers and patients in selecting the most appropriate treatments; assisting regulators in efficacy and safety determinations; helping payers make coverage and reimbursement decisions; and spurring scientists with translational insights. Reduced trial times and costs could enable more indications, reduced development cycle times, and improved system financial sustainability. Challenges to overcome range from statistical to operational to collaborative governance and data exchange.
format Online
Article
Text
id pubmed-5142736
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-51427362016-12-16 PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms Trusheim, MR Shrier, AA Antonijevic, Z Beckman, RA Campbell, RK Chen, C Flaherty, KT Loewy, J Lacombe, D Madhavan, S Selker, HP Esserman, LJ Clin Pharmacol Ther State of the Art Adaptive, seamless, multisponsor, multitherapy clinical trial designs executed as large scale platforms, could create superior evidence more efficiently than single‐sponsor, single‐drug trials. These trial PIPELINEs also could diminish barriers to trial participation, increase the representation of real‐world populations, and create systematic evidence development for learning throughout a therapeutic life cycle, to continually refine its use. Comparable evidence could arise from multiarm design, shared comparator arms, and standardized endpoints—aiding sponsors in demonstrating the distinct value of their innovative medicines; facilitating providers and patients in selecting the most appropriate treatments; assisting regulators in efficacy and safety determinations; helping payers make coverage and reimbursement decisions; and spurring scientists with translational insights. Reduced trial times and costs could enable more indications, reduced development cycle times, and improved system financial sustainability. Challenges to overcome range from statistical to operational to collaborative governance and data exchange. John Wiley and Sons Inc. 2016-10-19 2016-12 /pmc/articles/PMC5142736/ /pubmed/27643536 http://dx.doi.org/10.1002/cpt.514 Text en © 2016 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle State of the Art
Trusheim, MR
Shrier, AA
Antonijevic, Z
Beckman, RA
Campbell, RK
Chen, C
Flaherty, KT
Loewy, J
Lacombe, D
Madhavan, S
Selker, HP
Esserman, LJ
PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms
title PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms
title_full PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms
title_fullStr PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms
title_full_unstemmed PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms
title_short PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms
title_sort pipelines: creating comparable clinical knowledge efficiently by linking trial platforms
topic State of the Art
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5142736/
https://www.ncbi.nlm.nih.gov/pubmed/27643536
http://dx.doi.org/10.1002/cpt.514
work_keys_str_mv AT trusheimmr pipelinescreatingcomparableclinicalknowledgeefficientlybylinkingtrialplatforms
AT shrieraa pipelinescreatingcomparableclinicalknowledgeefficientlybylinkingtrialplatforms
AT antonijevicz pipelinescreatingcomparableclinicalknowledgeefficientlybylinkingtrialplatforms
AT beckmanra pipelinescreatingcomparableclinicalknowledgeefficientlybylinkingtrialplatforms
AT campbellrk pipelinescreatingcomparableclinicalknowledgeefficientlybylinkingtrialplatforms
AT chenc pipelinescreatingcomparableclinicalknowledgeefficientlybylinkingtrialplatforms
AT flahertykt pipelinescreatingcomparableclinicalknowledgeefficientlybylinkingtrialplatforms
AT loewyj pipelinescreatingcomparableclinicalknowledgeefficientlybylinkingtrialplatforms
AT lacombed pipelinescreatingcomparableclinicalknowledgeefficientlybylinkingtrialplatforms
AT madhavans pipelinescreatingcomparableclinicalknowledgeefficientlybylinkingtrialplatforms
AT selkerhp pipelinescreatingcomparableclinicalknowledgeefficientlybylinkingtrialplatforms
AT essermanlj pipelinescreatingcomparableclinicalknowledgeefficientlybylinkingtrialplatforms